Share chart Ultragenyx Pharmaceutical Inc.
Extended chart
Simple chart
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., биофармацевтическая компания, специализируется на выявлении, приобретении, разработке и коммерциализации новых продуктов для лечения редких и ультра-редких генетических заболеваний в Соединенных Штатах. Его биологические продукты включают Crysvita (буросумаб), антитело, нацеленное на фактор роста фибробластов 23, для лечения Х-связанной гипофосфатемии; и Mepsevii, заместительная ферментная терапия для лечения детей и взрослых с мукополисахаридозом VII. more detailsIPO date | 2014-01-31 |
---|---|
ISIN | US90400D1081 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 0 |
Сайт | http://www.ultragenyx.com |
Цена ао | 38.69 |
Change price per day: | 0% (38.69) |
---|---|
Change price per week: | -2.49% (39.68) |
Change price per month: | -7.53% (41.84) |
Change price per 3 month: | -11.57% (43.75) |
Change price per half year: | -29.93% (55.22) |
Change price per year: | -17.36% (46.82) |
Change price per 3 year: | -54.26% (84.58) |
Change price per 5 year: | -27.03% (53.02) |
Change price per year to date: | -10.89% (43.42) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
Vanguard Group Inc | 8673432 | 10.54 |
RTW Investments LP | 6887086 | 8.37 |
Blackrock Inc. | 5238400 | 6.37 |
Wellington Management Group, LLP | 4415029 | 5.36 |
Sands Capital Management, LLC | 4118008 | 5 |
Price (T.Rowe) Associates Inc | 3448698 | 4.19 |
State Street Corporation | 3252502 | 3.95 |
Federated Hermes, Inc. | 2446500 | 2.97 |
ClearBridge Investments, LLC | 2383492 | 2.9 |
Alkeon Capital Management LLC | 2241832 | 2.72 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 1.37M | 1960 (65 years) |
Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 806.19k | 1966 (59 years) |
Mr. Erik Harris | Executive VP & Chief Commercial Officer | 848.24k | 1971 (54 years) |
Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | N/A | 1971 (54 years) |
Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development | 331.33k | 1965 (60 years) |
Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 595.01k | 1978 (47 years) |
Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | N/A | 1965 (60 years) |
Mr. Thomas R. Kassberg | Chief Business Officer & Executive VP | 714.84k | 1960 (65 years) |
Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | N/A | 1978 (47 years) |
Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 1965 (60 years) |
Address: United States, Novato, CA , 60 Leveroni Court - open in Google maps, open in Yandex maps
Website: http://www.ultragenyx.com
Website: http://www.ultragenyx.com